Here, an IL-2v mutein is fused with the high-affinity fibroblast activation protein α (FAP) human IgG1 antibody 4B9, allowing this fusion protein to deliver the IL-2 variant to the surface of cancer-associated fibroblasts and pericytes that highly express FAP, without preferential activation of Treg cells. Here, IL2 is linked to cancer.